Scarica l'app Stockscreener
23.20
5.69%
-1.40
Dopo l'orario di chiusura:
23.20
Precedente Chiudi:
$24.60
Aprire:
$23.832
Volume 24 ore:
1,909
Relative Volume:
0.44
Capitalizzazione di mercato:
$2.16B
Reddito:
$136.33M
Utile/perdita netta:
$-56.34M
Rapporto P/E:
-30.92
EPS:
-0.7504
Flusso di cassa netto:
$-18.87M
1 W Prestazione:
-4.09%
1M Prestazione:
-18.25%
6M Prestazione:
-42.29%
1 anno Prestazione:
+29.97%
Intervallo 1D:
$23.20
$23.99
Intervallo di 1 settimana:
$23.20
$24.60
Portata 52W:
$17.09
$48.45
Ascentage Pharma Group International Adr Stock (AAPG) Company Profile
Nome
Ascentage Pharma Group International Adr
Settore
Industria
Telefono
-
Indirizzo
-
Compare AAPG vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AAPG
Ascentage Pharma Group International Adr
|
23.20 | 2.29B | 136.33M | -56.34M | -18.87M | -0.7504 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Ascentage Pharma Group International Adr Stock (AAPG) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-13 | Iniziato | Rodman & Renshaw | Buy |
| 2025-12-04 | Iniziato | Oppenheimer | Outperform |
| 2025-11-24 | Iniziato | Truist | Buy |
| 2025-11-10 | Iniziato | BTIG Research | Buy |
| 2025-11-05 | Iniziato | Piper Sandler | Overweight |
| 2025-03-27 | Iniziato | JP Morgan | Overweight |
Mostra tutto
Ascentage Pharma Group International Adr Borsa (AAPG) Ultime notizie
Rodman & Renshaw Initiates Ascentage Pharma Group International (AAPG) with Buy Rating, $48 Target - Finviz
Ascentage Pharma to Present at Guggenheim Biotech Summit as Late-Stage Oncology Pipeline Expands - TipRanks
Ascentage Pharma Group InternationalUnsponsored ADR (NASDAQ:AAPG) Given Consensus Rating of "Buy" by Analysts - MarketBeat
Ascentage Pharma Wins China IND Clearance for Next-Gen BTK Degrader APG-3288 - TipRanks
Ascentage Pharma Announces IND Clearance by the China CDE for BTK Degrader APG-3288 - GlobeNewswire Inc.
Ascentage Pharma Announces IND Clearance by the China CDE for BTK Degrader APG-3288 - Sahm
Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap UpTime to Buy? - MarketBeat
Ascentage Pharma Group International (NASDAQ:AAPG) Sees Large Volume IncreaseTime to Buy? - MarketBeat
Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) Sees Significant Increase in Short Interest - Defense World
Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap DownWhat's Next? - MarketBeat
Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) Short Interest Update - Defense World
Ascentage Pharma Details 2026 Global Innovation Strategy at J.P. Morgan Healthcare Conference - TipRanks
Ascentage Pharma Outlined its Global Innovation Strategy During Presentation at 44th Annual J.P. Morgan Healthcare Conference - Sahm
Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
Analysts Offer Insights on Healthcare Companies: BeOne Medicines (ONC) and Vertex Pharmaceuticals (VRTX) - The Globe and Mail
Ascentage Pharma Wins FDA IND Clearance for BTK Degrader APG-3288 to Enter Global Phase I Trial - TipRanks
Ascentage Pharma Announces IND Clearance by the U.S. Food and Drug Administration for BTK Degrader APG-3288 - Sahm
Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) Receives $48.50 Average Price Target from Brokerages - Defense World
Ascentage Pharma Group International (NASDAQ:AAPG) Stock Price Down 5.5%Should You Sell? - MarketBeat
Ascentage Pharma to Present at J.P. Morgan Healthcare Conference - TipRanks
Ascentage Pharma to Engage Investors at December 2025 Conferences - MSN
Ascentage Pharma Showcases Promising Data for Olverembatinib at ASH 2025 - The Globe and Mail
Ascentage Pharma showcases promising data for olverembatinib at ASH 2025 - MSN
Ascentage Pharma Unveils Promising Lisaftoclax Data at ASH 2025 - TipRanks
Cash per share of Ascentage Pharma Group International Unsponsored ADR – LSX:A40ZYR - TradingView
ETFs Investing in Ascentage Pharma Group International Unsponsored ADR Stocks - TradingView — Track All Markets
Cash per share of Ascentage Pharma Group International Unsponsored ADR – LS:A40ZYR - TradingView
Ascentage Pharma to Highlight Key Data from ASH 2025 in Upcoming Webcast - TipRanks
Ascentage Pharma Announces New RSU and Share Option Grants - TipRanks
Analysts’ Top Healthcare Picks: Amgen (AMGN), Opus Genetics (IRD) - The Globe and Mail
Ascentage Pharma’s Olverembatinib Shows Promise in Rare GIST Treatment - TipRanks
Ascentage Pharma Group International (NASDAQ:AAPG) Now Covered by Analysts at Truist Financial - Defense World
Ascentage Pharma Group International Adr Azioni (AAPG) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.24%
0.19%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):